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Abstract
Mortality related to methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) remains high, despite changes in the
epidemiology. To analyze the current predictive factors for mortality we conducted a prospective study in a large cohort of patients with
MRSA-BSI from21Spanish hospitals. Epidemiology, clinical data, therapy andoutcomewere recorded.AllMRSAstrainswere analysed, including
susceptibility to antibiotics and molecular characterization. Vancomycin MICs (V-MIC) were tested by the E-test and microdilution methods.
Time until death was the dependent variable in a Cox regression analysis. Overall, 579 episodes were included. Acquisition was nosocomial
in 59% and vascular catheter was the most frequent source (38%). A dominant PFGE genotype was found in 368 (67%) isolates, which belonged
to Clonal Complex (CC)5 and carried SCCmecIV and agr2. Microdilution V-MIC50 and V-MIC90 were 0.7 and 1.0 mg/L, respectively.
Initial therapy was appropriate in 66% of episodes. Overall mortality was observed in 179 (32%) episodes. The Cox-regression analysis
identiﬁed age >70 years (HR 1.88), previous fatal disease (HR 2.16), Pitt score >1 (HR 3.45), high-risk source (HR 1.85) and inappropriate
initial treatment (HR 1.39) as independent predictive factors formortality. CC5 andCC22 (HR 0.52 and 0.45) were associatedwith signiﬁcantly
lower mortality rates than CC8. V-MIC  1.5 did not have a signiﬁcant impact on mortality, regardless of the method used to assess it.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream
infection (BSI) has been a cause of concern in healthcare
systems around the world in recent decades, due to an
increase in its incidence and undesirable related outcomes [1].
Despite the recent epidemiological changes, MRSA clonal
replacement, clinical use of new antibiotics and improvement
in supportive therapies, mortality related to MRSA-BSI remains
close to 30% [2].
Avarietyof factorshavebeenassociatedwithworseoutcomes
among MRSA-BSI patients, including host characteristics, bacte-
rial genetic background and therapeutic management [3]. At
present, however, no predictors for mortality have been
deﬁnitively established, because only a few recent large prospec-
tive multicentre studies have analysed all these factors together.
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Vancomycin, which is the standard therapy forMRSA-BSI, has
recently been the focus of attention. Its suboptimal in vitro killing
activity for S. aureus compared with betalactams [4] and the
observation ofMIC creep inmany hospitals around theworld [5]
have raised questions about its suitability for use against MRSA
invasive infections [6,7]. Special concern has been raised during
the last decade regarding the impact on mortality of MRSA
strains with reduced vancomycin susceptibility [3,7–9].
This study aimed to assess the prognostic factors for
mortality among MRSA-BSI patients, taking into account the
current epidemiological data and carefully examining the
clinical impact of vancomycin susceptibility on mortality.
Methods
Study period and patients
The study was conducted from June 2008 to December 2009
at 21 Spanish hospitals. Four centres had <500 beds, nine had
500–1000 beds and eight had >1000 beds. An infectious
disease specialist prospectively followed adult patients
(>16 years old) with MRSA blood cultures previously detected
at the Microbiology Laboratory, and excluded the cases that
did not meet the inclusion criteria, such as lack of signs and
symptoms consistent with sepsis. A standardized protocol
with demographic and clinical information, including age, sex,
co-morbid conditions, source and acquisition, diagnostic
explorations, antibiotic treatment, follow-up and outcome
was followed. Strains were sent to a central laboratory for
further analysis.
Study design
All the episodes included in the study were used to assess the
prognostic factors for mortality, which was measured 30 days
after the ﬁrst blood culture. Two different models that only
differed in the method used to assess MRSA vancomycin
susceptibility (E-test or microdilution) were used. MICs were
stratiﬁed as follows: <1.5 and  1.5 lg/mL. Time until death
was the dependent variable in a Cox regression analysis and
was censored 30 days after the end of therapy or end of
follow-up. The prognostic factors for non-appropriate initial
antibiotic therapy were analysed in a logistic regression model.
Patients who received appropriate initial therapy were
included in an adjusted multivariate analysis designed to assess
the existence of differences in mortality related to the speciﬁc
antibiotic administered.
Deﬁnitions
Methicillin-resistant Staphylococcus aureus-BSI is deﬁned as the
presence of at least one positive blood culture for MRSA in a
blood sample from a patient with clinical ﬁndings consistent
with infection. Co-morbidity was measured by the Charlson
score, which stratiﬁes the associated diseases into an ordinal
scale. Patients were classiﬁed into three categories on the
McCabe scale according to their prognosis of survival before
the MRSA-BSI: non-fatal if death was expected within a period
longer than 5 years; ultimately fatal if death was expected
between 1 and 5 years; and rapidly fatal if it was expected in
the following year. Severity of disease was assessed by the Pitt
score. Three acquisition categories were considered according
to Friedman criteria: (i) nosocomial-BSI if the episode was
diagnosed at least 48 hours after the hospital admission, either
to the ICU or to a conventional hospital ward (non-ICU), and
if there were no signs or symptoms of infection at admission;
(ii) healthcare related-bacteraemia if the patient had had
contact with the healthcare system within the previous
3 months; and (iii) community-acquired otherwise. Source of
the BSI was deﬁned according to the CDC criteria [10]. BSI of
unknown source (primary) was deﬁned when its origin was
uncertain after careful examination of the clinical and micro-
biological data. It was considered high risk if the source was
lower respiratory tract, endocarditis or unknown [3]. Distant
extension was diagnosed in the presence of at least one distant
infection secondary to blood spread seeding. Persistence was
deﬁned as growth of MRSA in blood cultures after more than
48 h of appropriate antibiotic therapy. The initial antibiotic was
deﬁned as the antibiotics administered in the ﬁrst 48 h after
BSI onset, regardless of the microbiological information.
Deﬁnitive treatment was considered as the antimicrobials
administered after conducting microbiological sensitivity tests.
Antibiotic treatment was considered appropriate if the strain
was susceptible to at least one of the administered antibiotics,
with the exception of aminoglycosides, which were considered
inappropriate, regardless of the sensitivity tests. Source
eradication was considered if the catheter or foreign body
was removed, or if a surgical intervention or drainage of BSI
source was performed.
Susceptibility testing and molecular epidemiology of MRSA
isolates
Each hospital identiﬁed the strain and performed preliminary
susceptibility tests. Isolates were sent to a central reference
laboratory. All S. aureus were identiﬁed by latex agglutination
(Pastorex Staph-plus, Bio-Rad Laboratories, Madrid, Spain) and
DNase production (DNas E-test Agar, BioMerieux, Marcy
l’Etoile, France). Antimicrobial susceptibility of all MRSA
isolates was tested by the disk-diffusion method according to
the Clinical Laboratory Standard Institute (CLSI) guidelines
[11]. The antimicrobial agents tested were penicillin, oxacillin,
cefoxitin, erythromycin, clindamycin, gentamicin, tobramycin,
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ciproﬂoxacin, rifampicin, trimethoprim-sulphamethoxazole,
tetracycline, fosfomycin, vancomycin, teicoplanin, chloramphe-
nicol, daptomycin and linezolid. Minimum inhibitory concen-
tration (MIC) was determined by the microdilution method in
accordance with CLSI criteria by using commercial panels
(ESTEN 2009, Sensititre, Izasa, Barcelona, Spain) read visually.
Vancomycin MICs were also studied by E-test (BioMerieux) on
Mueller-Hinton agar, using a turbidity of 0.5 on the McFarland
scale.
Pulsed-ﬁeld gel electrophoresis (PFGE) was performed after
SmaI restriction of chromosomal DNA[12]. Restriction pat-
terns were interpreted in accordance with criteria published
elsewhere [13]. To deﬁne PFGE types the FINGERPRINTING
II software, version 3.0 (BioRad Laboratories, Inc., Madrid,
Spain) was applied.
A dendrogram was generated by the unweighted-pair group
method with arithmetic mean based on Dice coefﬁcients. To
deﬁne PFGE types the similarity coefﬁcient cut-off was set at
80%. Optimization and band position tolerance were both set
at 0.6%.Representative isolates of each PFGE type and subtype
were studied to determine the Multilocus Sequence Type
(MLST) [14] and the Staphylococcal Chromosome Cassette
mec (SCCmec) types [15]. MLSTs and SCCmec types were
further inferred for all the strains. The agr polymorphism and
the presence of genes encoding class S (lukS-PV) and class F
(lukF-PV) proteins for Panton–Valentine Leucocidine (PVL)
were studied by PCR in all the isolates, following the
methodology described elsewhere [16,17].
Statistical analysis
Continuous variables were compared using the Student’s t-test
or the Mann–Whitney U-test as appropriate. Qualitative and
stratiﬁed continuous variables were compared using Fisher’s
exact test or Pearson’s chi-squared test. Relative risks were
calculated with 95% conﬁdence intervals in a univariate analysis.
Time until death was the dependent variable in a Cox regression
analysis, and was censored 30 days after the end of therapy or
the end of follow-up. Administration of appropriate antibiotic
therapy was the dependent variable in a logistic regression
model. All the variables with theoretical clinical signiﬁcance and
those that achieved a p value<0.10 in the univariate analysiswere
included in the multivariate analysis, and adjusted odds ratios
(ORs) were calculated with 95% CI. Analyses were performed
using SPSS v15 (Microsoft, USA).
Ethical considerations
The study was approved by the Spanish Network for Research
in Infectious Diseases (REIPI) as well as the Institutional Review
Board of each participating centre. Because no direct patient
contact was planned, the requirement for informed consent
was waived. The data were de-identiﬁed in each centre and
only then transferred for analysis.
Results
Five hundred and ninety episodes of MRSA-BSI were con-
ﬁrmed. Eleven were excluded from the analysis due to lack of
information. Therefore, 579 episodes were ﬁnally included,
which are summarized in Table 1.
Twenty-ﬁve PFGE types were found among 552 available
isolates (Fig. 1). A dominant PFGE genotype (pulse-type 2) was
found in 368 (67%), all of which belonged to Clonal Complex
(CC) 5 (ST125 and ST146). They carried a SCCmec element
type IV and agr type 2. Forty-seven (9%) isolates of clonal type
ST228-agr2, a single locus variant of ST5, were considered a
separate clone based on its SCCmec polymorphism type I.
ST22-SCCmecIV-agr1 and ST8-SCCmecIV-agr1 represented
9% (48/552) and 8% (44/552), respectively, of all studied
strains. PVL was found to be positive in 15 isolates; 11 of them
belonged to ST8, three to ST125 and one to ST714. Among
PVL-positive isolates of ST8, six strains out of 11 belonged to
the USA300 clone. Vancomycin MIC (microdilution and E-test)
distribution according to the molecular characterization is
summarized in Table 2. Vancomycin MIC  1.5 lg/mL mea-
sured by microdilution and E-test was observed in 3.3% and
42.9% of the isolates, respectively. Linezolid MIC50 and MIC90
were 2 and 2 lg/mL and daptomycin MIC50 and MIC90 were
<0.5 and 1 lg/mL.
Initial antibiotic therapy was appropriate in 66% of episodes.
Factors related to inappropriate initial antibiotic therapy were
certain sources of infection (unknown source (OR 4.22), lower
respiratory tract (OR 3.55) and skin and soft tissues (OR
2.58)) and Pitt score  3 (OR 1.68; Table 3). The median delay
in starting appropriate antibiotic therapy was 1.8 days
(IQR 0–3). Antibiotics were administered for a median of
18 days (IQR 15–27). The source was eradicated or drained in
the ﬁrst 2 days in 35% of cases.
Overall mortality was observed in 179 (32%) episodes. The
Cox-regression analysis identiﬁed age >70 years (HR 1.88),
ultimately fatal or rapidly fatal disease (HR 2.16), Pitt >3 (HR
3.45), high-risk source (HR 1.85) and inappropriate initial
treatment (HR 1.39) as independent predictive factors for
mortality. CC5 (HR 0.52) and CC22 (HR 0.45) were identiﬁed
as protective factors compared with CC8 (Table 4). Vanco-
mycin MIC  1.5 lg/mL, measured either by the microdilu-
tion method (HR 1.71) or by E-test (HR 0.78), did not show a
signiﬁcant impact on mortality. Neither was vancomycin
MIC  2 lg/mL identiﬁed as an independent predictor for
mortality, regardless of the method used to assess it
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(microdilution, HR 0.83 (95% CI 0.11–6.05); E-test, HR 0.94
(95% CI 0.61–1.46)).
In the adjusted Cox-regression model comparing the initial
and deﬁnitive antibiotic therapies administered, no signiﬁcant
differences in mortality were found (Table 5a,b).
Discussion
This multicentre cohort study reinforces the concept that
recent trends towards aging, non-nosocomial acquisition,
extended use of new antibiotics and advances in medical
support [1,2] have not signiﬁcantly modiﬁed the high mortality
rates associated with MRSA-BSI, which remain close to 30%
[18]. We analysed the current prognostic factors for mortality,
taking into account potential clinical, microbiological and
therapeutic predictors. In our opinion, a number of our
results merit further discussion.
From a clinical perspective, age, co-morbidities, high-risk
sources and severity of sepsis were identiﬁed as independent
host predictors for mortality. All of these had been identiﬁed
in previous studies of MRSA-BSI [3,8,19]. A recent review [18]
showed age to be the strongest and most consistent predictor
for mortality in S. aureus bacteraemia. In contrast to other
studies [8], healthcare-related acquisition was not identiﬁed as
a risk factor for worse outcome, probably because of the
low mortality rate among episodes acquired during haemod-
ialysis (14%), which represented 19% of the non-nosocomial
cohort.
There is little information in the literature regarding the
inﬂuence of genetic background on the outcome of MRSA
infections. It remains unknown whether some MRSA clones
have a greater ability to cause invasive disease: some studies
have found signiﬁcant differences between them, but others
have not [20,21]. A recent study observed a greater number
of haematogenous complications in episodes caused by
strains belonging to CC5 and CC30 [22]. Interestingly, in
our study CC5 (ST125, ST146 and ST228) and ST22
(EMRSA15) were identiﬁed as protective factors compared
with CC8. Regarding the PVL gene, in agreement with other
authors [23], we found no relationship with worse
outcomes. This gene was only harboured by some of
the isolates in our study (3%), highlighting the current
low prevalence of typical MRSA community clones in
Spain [24].
We were particularly interested in assessing the clinical
impact of vancomycin susceptibility on mortality. We did not
ﬁnd an independent association with vancomycin
MIC  1.5 lg/mL, measured either by microdilution or by
E-test. These results contrast with those of other studies
TABLE 1. Summary of all episodes of methicillin-resistant
Staphylococcus aureus bloodstream infection characteristics
N episodes (%)
Clinical characteristics N = 579
Age Mean (SD) 69.1 (14.3)
Gender Woman 194 (34)
Charlson Median (ICR) 3 (2–6)
McCabe Non-fatal 279 (49)
Ultimately fatal 212 (37)
Rapidly fatal 82 (14)
Source Vascular catheter 218 (38)
Unknown source 94 (16)
Skin and soft tissues 81 (14)
Low respiratory tract 70 (12)
Surgical site infections 36 (6)
Urinary tract 28 (5)
Endocarditis 17 (3)
Osteoarticular 12 (2)
Suppurative thrombophlebitis 11 (2)
Distant secondary focus 105 (17)
Persistence 93 (23)
Foreign body presence 270 (47)
Acquisition Nosocomial 338 (59)
ICU 72 (13)
Healthcare related 238 (38)
Previous admission 78 (14)
Ambulatory assistance 57 (10)
Haemodialysis 42 (7)
Long-term care facilities 41 (7)
Community 20 (4)
Pitt score Median (ICR) 1 (0–3)
Microbiological studies N = 552
PFGE type 2 368 (67)
4 48 (9)
5 32 (6)
12 33 (6)
Other 71 (13)
agr type II 419 (76)
I 122 (22)
III 11 (2)
MLST- SCCmec CC5*—IV 371 (67)
ST22—IV 48 (9)
ST228—I 47 (9)
ST8—IV 44 (8)
Other 42 (8)
PVL 15 (3)
Microdilution vancomycin
median MIC (ICR)
(lg/mL)
0.73 (0.38–3)
E-test vancomycin
median MIC (ICR)
(lg/mL)
1.21 (0.38–4)
Treatment N = 579
Source drainage or catheter withdrawal within ﬁrst
48 hours
205 (35)
Appropriate initial antibiotic 371 (66)
Vancomycin 205 (55)
Linezolid 67 (18)
Daptomycin 44 (12)
Teicoplanin 28 (8)
Cotrimoxazole 10 (3)
Clindamycin 9 (2)
Other * 8 (2)
Deﬁnitive antibiotic 526 (91)
Vancomycin 230 (44)
Linezolid 104 (20)
Daptomycin 124 (24)
Teicoplanin 31 (6)
Cothrimoxazole 14 (3)
Clindamycin 4 (1)
Other * 10 (2)
ICU, intensive care unit; PFGE, pulsed-ﬁeld gel electrophoresis; MLST, multilocus
sequence typing; ST, sequence type; CC, clonal complex; SCCmec, staphylo-
coccal cassette chromosome; PVL, Panton–Valentine Leukocidin; MIC, minimum
inhibitory concentration; ICR, interquartile range; *CC5 includes ST125 and
ST146.
*Other antibiotics include: tigecyclin, quinolones and fosfomycin with imipe-
nem.
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that reported an association between higher vancomycin
MIC measured by E-test and mortality [3] or treatment
failure [25] among patients treated with vancomycin. Striking
results in two recent studies suggested that decreased
vancomycin susceptibility might be a marker of certain
unidentiﬁed host or strain factors, related to worse
outcomes: Aguado et al. [26] observed that E-test vanco-
mycin MIC  1.5 was the only independent predictive
factor for complicated MSSA bacteraemia treated with
betalactams, while Holmes et al. [27] found increased
(a) (b) (c)
FIG. 1. Molecular characterization of MRSA isolates. Shown from left to right are (a) a dendrogram comparing pulsed-ﬁeld gel electrophoresis
(PFGE) of SmaI macrorestriction fragments, (b) PFGE patterns and types (expressed by numbers), followed by (c) multilocus sequence typing (MLST)
and clonal complex (CC). The cut-off value to deﬁne PFGE types was set at 80%. Optimization and band position tolerance were both set at 0.6%.
TABLE 2. Distribution of vancomycin MIC (lg/mL) tested by microdilution and E-test methods among the three major clonal
complexes in the cohort of methicillin-resistant Staphylococcus aureus bloodstream infections
Vancomycin MIC (lg/mL)
 0.5 0.75 1 1.5 2 3 4 Total
CC 5 (SCCmec type IV, agr 2)
Microdilution 38 (10.2) 254 (68.5) 70 (18.9) 7 (1.9) 1 (0.3) 1 (0.3) 0 (0) 371
E-test 13 (3.5) 20 (5.4) 159 (42.9) 134 (36.1) 42 (11.3) 2 (0.5) 1 (0.3)
ST228 * (SCCmec type I, agr 2)
Microdilution 4 (8.6) 29 (61.7) 10 (21.3) 3 (6.4) 1 (2.1) 0 (0) 0 (0) 47
E-test 1 (2.1) 3 (6.4) 9 (19.1) 21 (44.7) 11 (23.4) 2 (4.3) 0 (0)
ST 8 (SCCmec type IV, agr 1)
Microdilution 16 (36.4) 25 (56.8) 2 (4.5) 1 (2.3) 0 (0) 0 (0) 0 (0) 44
E-test 6 (13.6) 13 (29.5) 20 (45.5) 5 (11.4) 0 (0) 0 (0) 0 (0)
ST 22 (†) (SCCmec type IV, agr 1)
Microdilution 37 (77.1) 8 (16.7) 1 (2.1) 2 (4.2) 0 (0) 0 (0) 0 (0) 48
E-test 17 (35.4) 17 (35.4) 9 (18.8) 3 (6.3) 2 (4.2) 0 (0) 0 (0)
Other clonal complexes
Microdilution 10 (23.8) 27 (64.3) 3 (7.1) 2 (4.8) 0 (0) 0 (0) 0 (0) 42
E-test 9 (21.4) 3 (7.1) 16 (38.1) 12 (28.6) 2 (4.8) 0 (0) 0 (0)
Total
Microdilution 105 (19.0) 343 (62.1) 86 (15.6) 15 (2.7) 2 (0.4) 1 (0.2) 0 (0) 552
E-test 46 (8.3) 56 (10.1) 213 (38.6) 175 (31.7) 57 (10.3) 4 (0.7) 1 (0.2)
*ST228, single locus variant of ST5.
†ST22, EMRSA15.
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mortality among episodes of S. aureus BSI with MIC  1.5,
regardless of the speciﬁc antibiotic therapy administered.
Like us, however, other authors did not ﬁnd a signiﬁcant
impact of vancomycin susceptibility on mortality [8,9].
Interestingly, Rojas et al. [9] did not observe any association
using either susceptibility method.
TABLE 3. Predictive factors for inappropriate initial therapy for methicillin-resistant Staphylococcus aureus bloodstream
infection
Appropriate initial antibiotic
n (%)
Inappropriate initial antibiotic
n (%)
Univariate Multivariate
OR p-Value OR (95% CI)
Age >70 193 (52.3) 117 (58.2) 1.27 0.18 1.11 (0.76–1.63)
Gender Female 126 (34.0) 65 (32.3) 0.93 0.65 1.01 (0.68–1.51)
Charlson score >5 96 (26.1) 65 (32.3) 1.35 0.11
McCabe Non-fatal disease 183 (49.7) 94 (47.5)
Ultimately fatal 136 (37.0) 71 (35.9) 1.02 0.93
Rapidly fatal 49 (13.3) 33 (16.7) 1.31 0.29
Pitt  3 287 (77.8) 166 (83.8) 0.68 0.09 1.68 (1.02–2.79)
Foreign body presence
Source
187 (50.4) 80 (39.8) 0.65 0.015 1.27 (0.79–2.03)
Skin and soft tissues 47 (12.7) 34 (16.9) 2.37 0.02 2.58 (1.35–4.90)
Surgical site infection 24 (6.5) 12 (6.0) 1.64 0.2
Urinary tract 20 (5.4) 8 (4.0) 1.3 0.55
Lower respiratory tract 35 (9.4) 33 (16.4) 3.09 <0.001 3.55 (1.76–7.15)
Unknown 41 (11.1) 49 (24.4) 3.91 <0.001 4.22 (2.25–7.93)
Distant secondary focus 76 (20.7) 25 (12.5) 0.65 0.015 0.64 (0.37–1.10)
Acquisition Nosocomial 222 (60.0) 111 (55.8)
Non-nosocomial* 148 (40.0) 88 (44.2) 1.19 0.33
*Non-nosocomial acquisition includes healthcare-related and community acquisitions.
TABLE 4. Predictive factors for mortality due to methicillin-resistant Staphylococcus aureus bloodstream infection. Univariate
and multivariate analyses
30-day deaths
n (%)
30-day survivors
n (%)
Univariate
Multivariate analysis
with microdilution
vancomycin MIC  1.5
Multivariate analysis
with E-test
vancomycin
MIC  1.5
HR p-Value HR (95% CI) HR (95% CI)
Clinical characteristics
Age >70 121(68.0) 183(48.4) 1.80 <0.001 1.88 (1.39–2.54) 1.89 (1.40–2.54)
Gender Woman 64 (35.8) 121(32.0) 1.12 0.43 1.31 (0.98–1.77) 1.29 (0.97–1.74)
Charlson >5 63 (35.2) 94 (25.0) 1.52 0.003 1.12 (0.82–1.53) 1.15 (0.85–1.57)
McCabe Non-fatal 58 (21.6) 211(58.4)
Ultimately or rapidly fatal 119(67.2) 163(43.6) 2.39 <0.001 2.16 (1.56–2.98) 2.04 (1.49–2.81)
Pitt score >3 73 (41.7) 40 (10.6) 3.48 <0.001 3.45 (2.57–4.76) 3.66 (2.69–4.98)
Acquisition Non-nosocomial * 74 (41.6) 157(41.8) 0.91 0.47
High-risk Source 86 (48.0) 86 (22.8) 2.13 <0.001 1.85 (1.33–2.56) 1.77 (1.28–2.46)
Endocarditis 8 (4.5) 9 (2.4) 1.60 0.042
Low respiratory tract 32 (17.9) 35 (9.3) 1.77 0.002
Unknown 46 (25.7) 42 (11.1) 1.89 <0.001
Foreign body presence 73 (40.8) 189(50.0) 0.76 0.045 0.82 (0.59–1.14) 0.84 (0.61–1.10)
Distant secondary focus 29 (16.4) 71 (18.9) 0.79 0.167 0.92 (0.63–1.34) 0.93 (0.64–1.36)
Microbiological studies
agr type I 42 (24.1) 75 (21.1)
II 129(74.1) 274(77.0) 0.86 0.34
III 3 (1.7) 7 (2.0) 0.70 0.56
PFGE type Other 24 (13.8) 40 (11.2)
4 12 (6.9) 36 (10.1) 0.65 0.17
5 10 (5.7) 20 (5.6) 1.01 0.97
2 112(64.4) 244(68.5) 0.85 0.44
12 16 (9.4) 16 (4.5) 1.49 0.19
Clonal complex CC8 20 (11.7) 23 (6.6) 1.25 0.52
CC5 † 129(75.0) 271(77.7) 0.64 0.049 0.52 (0.33–0.83) 0.58 (0.36–0.94)
CC22 12 (7.0) 37 (10.6) 0.50 0.032 0.45 (0.22–0.89) 0.46 (0.23–0.91)
Other 12 (7.0) 21 (6.0) 0.75 0.40
PVL 5 (2.9) 9 (2.5) 1.00 0.99
Microdilution vancomycin MIC 1.5 7 (4.0) 11 (3.1) 1.56 0.13 1.71 (0.92–3.19)
Microdilution vancomycin MIC 2 1 (0.6) 2 (0.6) 0.78 0.76
E-test vancomycin MIC 1.5 69 (39.7) 160(44.9) 0.78 0.08 0.78 (0.58–1.05)
E-test vancomycin MIC 2 20 (11.5) 39 (11.0) 0.85 1.04
Initial treatment (<48 hours)
Source drainage or catheter withdrawal 49 (27.4) 153(40.5) 0.64 0.002 0.93 (0.63–1.36) 0.89 (0.61–1.29)
Inppropriate initial antibiotic 72 (41.1) 125(33.2) 1.39 0.014 1.39 (1.04–1.86) 1.37 (1.02–1.83)
PFGE, pulsed-ﬁeld gel electrophoresis; MLST, multilocus sequence type; PVL, Panton–Valentine Leucocidine; MIC, minimum inhibitory concentration (lg/mL).
*Non-nosocomial acquisition includes healthcare-related and community acquisitions.
†CC5 includes ST125, ST146 and ST228.
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In our opinion, these contradictory results between studies
might have two complementary explantions: ﬁrst, according to
our results and the ﬁndings of Holmes et al. [27], certain
clones might have an independent association with mortality.
Therefore, because vancomycin MIC differs from one clone to
another, it is reasonable to hypothesize that the distinct clonal
distribution in countries can inﬂuence the impact of vancomy-
cin susceptibility observed in different studies. Secondly, the
low correlation between E-test and microdilution, which is
illustred in Table 2 [28], might also lead to these different
observed results. In our opinion, as Rojas et al. [9] stressed,
there is lack of evidence in favour of using the E-test instead of
the recommended microdilution method to assess MRSA
vancomycin MIC. As far as we know, only one previous study
found an association between vancomycin MIC  2 lg/mL
and mortality, using the microdilution method [19]. A recent
meta-analysis of MRSA BSI studies that assessed vancomycin
MICs by E-test concluded that while MIC  1.5 lg/mL was
not associated with higher mortality, MIC  2 was [7]. In
contrast, our study and others [29] did not ﬁnd an indepen-
dent association with E-test vancomycin MICs  2. In
summary, we believe that more studies will be needed to
resolve this controversy.
As regards therapeutic management, the initial therapy was
inappropriate in 34% of the episodes. It was also identiﬁed as
an independent predictive factor for mortality, as in previous
studies [3,30]. This is an interesting observation because
modifying this factor might reduce the number of related
deaths. In our study, patients with lower Pitt scores and
speciﬁc sources had a signiﬁcantly higher risk of receiving initial
inappropriate antibiotic therapy. Interestingly, we found no
statistical differences in mortality in relation to the type of
appropriate antibiotics used as initial or deﬁnitive therapy.
However, we stress that this last analysis is limited because the
choice of antibiotic was not controlled and there may have
been some confounding factors in the variables regarding the
therapy. Also, vancomycin serum levels were not assessed in
this study. Therefore, conclusions regarding the impact of
antibiotic therapy should be reached with caution.
In conclusion, we identiﬁed several prognostic factors for
mortality in a large cohort of patients and provide support for
the concept that host and bacterial characteristics, as well as
initial therapy, have implications for MRSA-BSI outcomes. In
contrast, higher vancomycin MIC had no impact on mortality,
regardless of the method used to assess it. Special attention
should be paid to patients with one or some of these
predictors, in order to ensure the administration of correct
initial therapy.
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